Recombinant Active Human EGFR (L718Q L858R) Mutant Protein, GST-tagged

• Cat.No.: EGFR-23H
• Product Overview: Recombinant human EGFR (L718Q L858R) (668-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.

Specification

• Description: The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor, thus inducing receptor dimerization and tyrosine autophosphorylation leading to cell proliferation. Mutations in this gene are associated with lung cancer. EGFR is a component of the cytokine storm which contributes to a severe form of Coronavirus Disease 2019 (COVID-19) resulting from infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
• Source: Insect cell
• Species: Human
• Tag: GST
• Molecular Mass: Approx 89~100 kDa
• Purity: > 80%
• Stability: One year at -70 centigrade from data of shipment.
• Storage: Store product at –70 centigrade. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
• Concentration: 0.05 μg/μL
• Storage Buffer: Recombinant protein stored in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM glutathione, 0.1 mM EDTA, 0.25 mM DTT, 25% glycerol.
• Shipping: Dry ice
• Protein length: 668-end

Gene Information

• Gene Name: EGFR epidermal growth factor receptor [ Homo sapiens (human) ]
• Official Symbol: EGFR
• Synonyms: EGFR; epidermal growth factor receptor; ERBB; ERRP; HER1; mENA; ERBB1; PIG61; NISBD2; epidermal growth factor receptor; EGFR vIII; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; cell growth inhibiting protein 40; cell proliferation-inducing protein 61; epidermal growth factor receptor tyrosine kinase domain; erb-b2 receptor tyrosine kinase 1; proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; EC 2.7.10.1
• Gene ID: 1956
• mRNA Refseq: NM_005228
• Protein Refseq: NP_005219
• MIM: 131550
• UniProt ID: P00533

Reviews

09/05/2022

The powerful biological activity of EGFR combined with its high purity makes the experimental results highly reproducible, which is of great significance in the field of scientific research.

09/26/2019

Due to the short half-life and high clearance characteristics of EGFR, they can better adapt to the needs of clinical treatment and provide more treatment options for patients.

03/23/2019

The production process of EGFR uses advanced biotechnology, which makes the production process more efficient and environmentally friendly, and reduces the consumption of human and material resources.

Q&As

What biological processes of human embryonic development and tissue regeneration is EGFR associated with?

It is associated with biological processes in human embryonic development and tissue regeneration.

Why does EGFR-inhibiting drug therapy have adverse reactions?

EGFR inhibits adverse drug reactions such as rash, inflammation, and diarrhea during drug treatment.

What is the role of EGFR in tumor treatment?

The role of EGFR in tumor treatment is to act as a molecular marker and can be used as a prognostic indicator and monitor tumor progression; at the same time, EGFR mutations can also be targeted for targeted therapy.

What are the general methods used for EGFR gene mutation testing?

EGFR gene mutation detection generally uses PCR, fluorescence in situ hybridization, and direct sequencing.

What other drugs can EGFR inhibitors be combined with to increase efficacy?

The combination of EGFR inhibitors with chemotherapy drugs, radiotherapy, immunotherapy, etc. can increase the efficacy of treatment and reduce the occurrence of adverse reactions.

How do EGFR mutations affect the efficacy of targeted therapies?

EGFR mutations can have a significant impact on the efficacy of targeted therapies, and patients with mutations have higher response rates.